{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:15:23Z","timestamp":1788830123210,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd013818","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000}}],"reference-count":95,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013818.pub2","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T04:47:14Z","timestamp":1665722834000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis"],"prefix":"10.1002","volume":"2022","author":[{"given":"William D","family":"Renton","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of General Medicine; The Royal Children's Hospital; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University of Colorado School of Medicine; Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan G","family":"Palestine","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University of Colorado School of Medicine; Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"10.1002\/14651858.CD013818.pub2-BIB0001|cit1","unstructured":"Adalimumab dans l\u2019Arthrite Juv\u00e9nile Idiopathique pour le traitement de l\u2019UV\u00e9ITE (\u00e9tude ADJUVITE) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-019441-26\/FR"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0002|cit2","unstructured":"Effect of adalimumab for the treatment of uveitis in juvenile idiopathic arthritis https:\/\/clinicaltrials.gov\/show\/NCT01385826"},{"issue":"7","key":"10.1002\/14651858.CD013818.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","article-title":"ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis","volume":"77","author":"Quartier","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013818.pub2-BIB0004|cit4","first-page":"455","article-title":"Adjuvite: a double-blind, randomized, placebo-controlled trial of Adalimumab in juvenile idiopathic arthritis associated uveitis","volume":"15","author":"Quartier","year":"2017","journal-title":"Pediatric Rheumatology"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/annrheumdis-2016-eular.2362","article-title":"Adjuvite: a double-blind, randomized, placebo-controlled trial of adalimumab in juvenile idiopathic arthritis associated uveitis","volume":"75","author":"Quartier","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Liu DT Chan A Assessment of inflammatory response in a study of uveitis associated with juvenile idiopathic arthritis: comment on the article by Smith et al Arthritis and Rheumatism 2005 53 6 986; author reply 986 7","DOI":"10.1002\/art.21597"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0007|cit7","unstructured":"TNRF:Fc to treat eye inflammation in juvenile rheumatoid arthritis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00001862"},{"issue":"1","key":"10.1002\/14651858.CD013818.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"18-23","DOI":"10.1002\/art.20904","article-title":"A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"53","author":"Smith","year":"2005","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Smith JA Thompson DJ Whitcup SM Suhler E Clarke G Smith S Reply Arthritis and Rheumatism 2005 53 986 7","DOI":"10.1002\/art.21598"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013818.pub2-BIB0010|cit10","first-page":"200","article-title":"Comparison of regression methods for the cost effectiveness analysis of clinical trials with a small population size: the sycamore and folated trials","volume":"18","author":"Culeddu","year":"2017","journal-title":"Trials"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0011|cit11","unstructured":"Randomised control trial of the clinical effectiveness, safety and cost effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis. - SYCAMORE https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-021141-41\/GB"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ajo.2019.06.007","article-title":"Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the Bristol participants of the SYCAMORE Trial","volume":"207","author":"Horton","year":"2019","journal-title":"American Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD013818.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ophtha.2018.09.043","article-title":"Cost-effectiveness analysis of adalimumab for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"126","author":"Hughes","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0014|cit14","unstructured":"The clinical effectiveness, safety and cost effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis https:\/\/www.isrctn.com\/ISRCTN10065623"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1745-6215-15-14","article-title":"A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)","volume":"15","author":"Ramanan","year":"2014","journal-title":"Trials"},{"issue":"15","key":"10.1002\/14651858.CD013818.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta23150","article-title":"Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT","volume":"23","author":"Ramanan","year":"2019","journal-title":"Health Technology Assessment (Winchester, England)"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/annrheumdis-2016-eular.6053","article-title":"Adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis: the sycamore trial","volume":"75","author":"Ramanan","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"17","key":"10.1002\/14651858.CD013818.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD013818.pub2-BIB0019|cit19","first-page":"S3932","article-title":"A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis","volume":"67","author":"Ramanan","year":"2015","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0020|cit20","first-page":"486","article-title":"A randomised, double-blind, parallel study to compare rates of remission (inactive disease) in patients with JIA on MTX treatment alone versus a combination of MTX and etanercept","volume":"77","author":"Alexeeva","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0021|cit21","unstructured":"Remission induction by etanercept in enthesitis related arthritis JIA-patients (juvenile undifferentiated spondylarthropathy) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2010-020423-51\/DE"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0022|cit22","unstructured":"A study of Baricitinib in children and young adults with JIA associated eye inflammation https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000119-10\/FR 2019 (first received 29 May 2019)"},{"issue":"3","key":"10.1002\/14651858.CD013818.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/bjo.2006.108050","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"Mansour","year":"2007","journal-title":"British Journal of Ophthalmology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013818.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/annrheumdis-2020-eular.6367","article-title":"Certolizumab therapy in refractory uveitis due to immune-mediated inflammatory diseases (IMID). multicenter study of 39 patients","volume":"79","author":"Martin-Varillas","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0025|cit25","unstructured":"The safety and efficacy of a tumor necrosis factor receptor fusion protein on uveitis associated with juvenile rheumatoid arthritis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00012506"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0026|cit26","unstructured":"Multi center prospective registry of infliximab use for childhood uveitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00589628"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0027|cit27","first-page":"234","article-title":"Prospective study of infliximab for treatment of pediatric uveitis","volume":"62","author":"Rabinovich","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD013818.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1097\/RHU.0000000000001707","article-title":"Weekly adalimumab, an effective alternative for refractory uveitis in children","volume":"28","author":"Roberts","year":"2022","journal-title":"Journal of Clinical Rheumatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD013818.pub2-BIB0029|cit29","first-page":"S1609","article-title":"Treatment of non-infectious uveitis: a comparative long-term study between biologic therapy with adalimumab and two conventional disease-modifying antirheumatic drugs","volume":"69","author":"Romero","year":"2017","journal-title":"Arthritis and Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD013818.pub2-BIB0030|cit30","first-page":"366","article-title":"Adalimumab can control uveitis within the framework of a juvenile idiopathic arthritis (JIA)","volume":"42","author":"Ruchalla","year":"2017","journal-title":"Aktuelle Rheumatologie"},{"issue":"7","key":"10.1002\/14651858.CD013818.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A prospective trial of infliximab therapy for refractory uveitis: Preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Archives of Ophthalmology"},{"issue":"17","key":"10.1002\/14651858.CD013818.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJMe1701811","article-title":"Adalimumab in the treatment of uveitis in juvenile idiopathic arthritis","volume":"376","author":"Thorne","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0033|cit33","unstructured":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01015547"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12969-019-0370-1","article-title":"Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial","volume":"17","year":"2019","journal-title":"Pediatric Rheumatology Online Journal"},{"issue":"9","key":"10.1002\/14651858.CD013818.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): A multicentre randomised open-label clinical trial","volume":"70","author":"Tynj\u00e4l\u00e4","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013818.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1186\/s13063-020-04796-z","article-title":"Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST\u2014Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial","volume":"21","author":"Acharya","year":"2020","journal-title":"Trials"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0037|cit37","unstructured":"Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial (ADJUST) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-000412-29\/GB"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0038|cit38","unstructured":"Adalimumab in JIA-associated Uveitis Stopping Trial https:\/\/clinicaltrials.gov\/show\/NCT03816397"},{"issue":"6","key":"10.1002\/14651858.CD013818.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.40885","article-title":"2019\u00a0American College of Rheumatology\/Arthritis foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis","volume":"71","author":"\u00a0Ringold","year":"2019","journal-title":"Arthritis and\u00a0Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD013818.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/acr.23610","article-title":"Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis","volume":"71","author":"Angeles-Han","year":"2019","journal-title":"Arthritis Care & Research (Hoboken)"},{"issue":"4716","key":"10.1002\/14651858.CD013818.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1126\/science.3895437","article-title":"Passive immunization against cachectin\/tumor necrosis factor protects mice from lethal effect of endotoxin","volume":"229","year":"1985","journal-title":"Science"},{"issue":"1","key":"10.1002\/14651858.CD013818.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","article-title":"Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial","volume":"77","author":"Brunner","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013818.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12969-018-0266-5","article-title":"Outcomes of non-infectious paediatric uveitis in the era of biologic therapy","volume":"16","author":"Cann","year":"2018","journal-title":"Pediatric Rheumatology Online Journal"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0044|cit44","unstructured":"Cassedy A Altaye M Andringa J Cooper AM Drews-Botsch C Assessing the validity and reliability of the Effects of Youngsters' Eyesight on Quality of Life (EYE-Q) questionnaire among children with uveitis Arthritis Care & Research (Hoboken) 10.1002\/acr.24491"},{"issue":"8","key":"10.1002\/14651858.CD013818.pub2-BIB0045|cit45","first-page":"1167","article-title":"Longterm safety and efficacy of adalimumab andiInfliximab for uveitis associated with juvenile idiopathic arthritis","volume":"45","author":"Cecchin","year":"2018","journal-title":"\u00a0Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD013818.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12969-016-0088-2","article-title":"Juvenile idiopathic arthritis-associated uveitis","volume":"14","year":"2016","journal-title":"Pediatric Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD013818.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12969-016-0085-5","article-title":"\u00a0Clinical outcome measures in juvenile idiopathic arthritis","volume":"14","author":"Consolaro","year":"2016","journal-title":"Pediatric Rheumatology Online Journal"},{"issue":"8","key":"10.1002\/14651858.CD013818.pub2-BIB0048|cit48","first-page":"1107","article-title":"Consensus-based recommendations for the management of\u00a0uveitis\u00a0associated with juvenile idiopathic arthritis: the SHARE initiative","volume":"77","author":"\u00a0Foeldvari","year":"2018","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6","key":"10.1002\/14651858.CD013818.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.survophthal.2015.06.004","article-title":"Anti-tumor necrosis factor-\u03b1 therapy in uveitis","volume":"60","year":"2015","journal-title":"Survey of Ophthalmology"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0050|cit50","unstructured":"Covidence Veritas Health Innovation"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch10"},{"issue":"3","key":"10.1002\/14651858.CD013818.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1006\/jaut.1998.0197","article-title":"Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis","volume":"11","year":"1998","journal-title":"Journal of Autoimmunity"},{"issue":"3","key":"10.1002\/14651858.CD013818.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF00915816","article-title":"Ocular inflammatory effects of intravitreally injected tumor necrosis factor-alpha and endotoxin","volume":"14","year":"1990","journal-title":"Inflammation"},{"issue":"1","key":"10.1002\/14651858.CD013818.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12969-019-0345-2","article-title":"Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)","volume":"17","author":"Foeldvari","year":"2019","journal-title":"Pediatric Rheumatology Online Journal"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0055|cit55","unstructured":"Tumor Necrosis Factor (TNF) Inhibitors www.ncbi.nlm.nih.gov\/books\/NBK482425\/"},{"issue":"2","key":"10.1002\/14651858.CD013818.pub2-BIB0056|cit56","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0057|cit57","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"issue":"1","key":"10.1002\/14651858.CD013818.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2012.07.052","article-title":"Risk factors for loss of visual acuity among patients with\u00a0uveitis\u00a0associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study","volume":"120","author":"\u00a0Kempen","year":"2013","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD013818.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.semarthrit.2018.11.004","article-title":"Update of the evidence based, interdisciplinary guideline for anti-inflammatory treatment of\u00a0uveitis\u00a0associated with juvenile idiopathic arthritis","volume":"49","author":"Minden","year":"2019","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD013818.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13075-020-02166-3","article-title":"Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany","volume":"22","author":"Heiligenhaus","year":"2020","journal-title":"Arthritis Research & Therapy"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Welch V Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0062|cit62","doi-asserted-by":"crossref","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch8"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0063|cit63","doi-asserted-by":"crossref","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"7","key":"10.1002\/14651858.CD013818.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology\u00a0"},{"issue":"3","key":"10.1002\/14651858.CD013818.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3899\/jrheum.091463","article-title":"Tumor necrosis factor and anti-tumor necrosis factor therapies","volume":"85","year":"2010","journal-title":"Journal of Rheumatology.\u00a0Supplement"},{"issue":"6","key":"10.1002\/14651858.CD013818.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.preteyeres.2010.08.003","article-title":"Mechanisms of TNF\u03b1 regulation in uveitis: focus on RNA-binding proteins","volume":"29","year":"2010","journal-title":"Progress in Retinal and Eye Research"},{"issue":"2","key":"10.1002\/14651858.CD013818.pub2-BIB0068|cit68","first-page":"165","article-title":"Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of\u00a0uveitis","volume":"168","author":"\u00a0Copland","year":"2012","journal-title":"Clinical and Experimental\u00a0Immunology"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fmed.2019.00104","article-title":"Anti-TNF drugs for chronic uveitis in adults-a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Leal","year":"2019","journal-title":"Frontiers in Medicine (Lausanne)"},{"issue":"6","key":"10.1002\/14651858.CD013818.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/art.21597","article-title":"Assessment of inflammatory response in a study of uveitis associated with juvenile idiopathic arthritis: comment on the article by Smith et al","volume":"53","author":"Liu","year":"2005","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD013818.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013818.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013818.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12969-019-0330-9","article-title":"Defining outcome measures in juvenile idiopathic arthritis associated uveitis by a systematic review analysis: do we need a consensus?","volume":"17","year":"2019","journal-title":"Pediatric Rheumatology Online Journal"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0074|cit74","doi-asserted-by":"crossref","unstructured":"McKenzie JE Brennan SE Ryan RE Thomson HJ Johnston RV Chapter 9: Summarizing study characteristics and preparing for synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch9"},{"issue":"11","key":"10.1002\/14651858.CD013818.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflammatory Bowel Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013818.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12348-020-00202-6","article-title":"A review of ocular adverse events of biological anti-TNF drugs","volume":"10","author":"Nicolela Susanna","year":"2020","journal-title":"Journal of Ophthalmic Inflammation and Infection\u00a0"},{"issue":"9783","key":"10.1002\/14651858.CD013818.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile idiopathic arthritis","volume":"377","author":"Prakken","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0078|cit78","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration, 2019"},{"issue":"12","key":"10.1002\/14651858.CD013818.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"2299\u2013306","DOI":"10.1016\/j.ophtha.2004.06.014","article-title":"Ocular complications of pediatric uveitis","volume":"111","author":"Rosenberg","year":"2004","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD013818.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/bjo.80.4.332","article-title":"Causes and frequency of blindness in patients with intraocular inflammatory disease","volume":"80","author":"Rothova","year":"1996","journal-title":"British Journal of\u00a0Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD013818.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000055677","article-title":"Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis","volume":"33","author":"\u00a0Marcos Mart\u00edn","year":"2001","journal-title":"Ophthalmic Research"},{"issue":"6","key":"10.1002\/14651858.CD013818.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jpeds.2006.08.044","article-title":"Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents","volume":"149","author":"Saurenmann","year":"2006","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0083|cit83","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s).\u00a0Cochrane Handbook for Systematic Reviews of Interventions\u00a0version 6.0 (updated July 2019). Cochrane, 2019 Available from\u00a0www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch14"},{"issue":"4","key":"10.1002\/14651858.CD013818.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.berh.2018.01.002","article-title":"Juvenile idiopathic arthritis-associated uveitis","volume":"31","year":"2017","journal-title":"Best Practice\u00a0and Research:\u00a0Clinical Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD013818.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/rheumatology\/kes186","article-title":"Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach","volume":"52","year":"2013","journal-title":"Rheumatology"},{"issue":"7","key":"10.1002\/14651858.CD013818.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/acr.22214","article-title":"Current evidence of anti-tumor necrosis factor alpha treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs","volume":"66","author":"Simonini","year":"2014","journal-title":"Arthritis Care & Research"},{"issue":"1","key":"10.1002\/14651858.CD013818.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/ceo.13856","article-title":"Recommendations for the management of childhood juvenile idiopathic arthritis-type chronic anterior uveitis","volume":"49","author":"Smith","year":"2021","journal-title":"Clinical & Experimental Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD013818.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-019-1108-3","article-title":"Under-utilisation of reproducible, child appropriate or patient reported outcome measures in childhood uveitis interventional research","volume":"14","author":"Solebo A","year":"2019","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013818.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/bjophthalmol-2018-313789","article-title":"Areas of agreement in the management of childhood non-infectious chronic anterior uveitis in the UK","volume":"104","author":"Solebo","year":"2020","journal-title":"British Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD013818.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"American Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD013818.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ajo.2021.03.055","article-title":"Classification Criteria for Juvenile Idiopathic Arthritis-Associated Chronic Anterior Uveitis","volume":"228","author":"Standardization of Uveitis Nomenclature Working Group","year":"2021","journal-title":"American Journal of Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD013818.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/ard.2006.058248","article-title":"Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis","volume":"66","author":"Tynjala","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD013818.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3109\/09273948.2014.926937","article-title":"Pathophysiology of JIA-associated uveitis","volume":"22","year":"2014","journal-title":"Ocular Immunology and Inflammation"},{"issue":"5 Suppl1","key":"10.1002\/14651858.CD013818.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.semarthrit.2005.01.009","article-title":"Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab","volume":"34","author":"Wallis","year":"2005","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD013818.pub2-BIB0095|cit95","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013818","article-title":"Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis","author":"Jung","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T03:47:55Z","timestamp":1733284075000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013818.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Eyes and Vision Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":95,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013818.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]}}}